若和

Ruohe Biotech is a Shanghai-based biotechnology company specializing in the discovery and development of next-generation targeted protein degradation (TPD) therapies, with a primary focus on molecular glues. The company utilizes its proprietary discovery platform to identify novel E3 ligase ligands and glue molecules that can induce the degradation of previously undruggable protein targets. Ruohe Biotech's pipeline is primarily directed toward high-value indications in oncology and autoimmune diseases. By leveraging structural biology, computational chemistry, and high-throughput screening, the company aims to expand the scope of TPD beyond traditional PROTAC approaches. Ruohe Biotech is backed by prominent venture capital firms and is positioned as an emerging leader in the Chinese molecular glue landscape.